Reviewing Bioventus (NYSE:BVS) and Presbia (OTCMKTS:LENSF)

Bioventus (NYSE:BVS) and Presbia (OTCMKTS:LENSF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Insider and Institutional Ownership

62.9% of Bioventus shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 74.2% of Presbia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Bioventus and Presbia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	3	0	2.75
Presbia	0	0	0	0	0.00

Bioventus currently has a consensus price target of $13.75, indicating a potential upside of 90.18%. Given Bioventus’ stronger consensus rating and higher possible upside, equities analysts plainly believe Bioventus is more favorable than Presbia.

Risk and Volatility

Bioventus has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Presbia has a beta of 5.91, indicating that its stock price is 491% more volatile than the S&P 500.

Profitability

This table compares Bioventus and Presbia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Presbia	N/A	N/A	N/A

Earnings and Valuation

This table compares Bioventus and Presbia”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$564.14 million	1.06	-$156.23 million	N/A	N/A
Presbia	N/A	N/A	N/A	N/A	N/A

Presbia has lower revenue, but higher earnings than Bioventus.

Summary

Bioventus beats Presbia on 7 of the 10 factors compared between the two stocks.

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.